Compare CECO & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | SLNO |
|---|---|---|
| Founded | 1966 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 2002 | 2014 |
| Metric | CECO | SLNO |
|---|---|---|
| Price | $54.19 | $34.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $77.75 | ★ $108.00 |
| AVG Volume (30 Days) | 748.5K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 280.56 | 108.90 |
| EPS | ★ 1.37 | 0.39 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | $24.84 | $155.44 |
| Revenue Next Year | $11.51 | $57.99 |
| P/E Ratio | ★ $39.62 | $94.31 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $17.57 | $32.63 |
| 52 Week High | $81.72 | $89.12 |
| Indicator | CECO | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 32.76 |
| Support Level | $44.68 | $32.63 |
| Resistance Level | $63.98 | $44.60 |
| Average True Range (ATR) | 3.88 | 2.45 |
| MACD | -0.91 | -0.18 |
| Stochastic Oscillator | 18.03 | 14.19 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.